PDCD1 and neoplasm: Tumor-associated MPs may also alter the behavior of the human cellular immune system, impacting the efficacy of recently developed immune checkpoint inhibitors (PD-1, PD-L1, etc.)and affecting T lymphocytes, leading to disease progression (133–136).